Upcoming 2023 Webinars for MDS Patients & Caregivers
We have planned a comprehensive series of webinars for 2023 bringing experts and the MDS community together to provide educational information, best practices, tools, and resources.
Whether you are a newly diagnosed patient, a long-term survivor, or caregiver, our webinar series will have something for you.
We will be collaborating with renowned hematology professionals who will be addressing key topics and questions you may have using language that is easy to understand in a 90-minute format that will include live Q&A opportunities for all participants.
Register now for our webinars planned for this series. Led by top thought leaders in the field, you can be assured you are getting information you can trust.
- April 1, 2023: Low-Risk MDS @12 pm ET
Speaker: Guillermo Garcia-Manero, MD; Chief, Section of MDS, MD Anderson Cancer Center
In this webinar, Dr. Garcia-Manero will highlight recent advances benefitting patients with Low-Risk MDS.
- April 22, 2023: Psychological Well-Being and MDS @12 pm ET
Speaker: Hermioni L. Amonoo, MD, MPP; Assistant Professor, Psychiatry, Harvard Medical School; Associate Program Director, Psychiatry, Brigham And Women’s Hospital
In this webinar, Dr. Hermioni Amonoo will share her tools for taking care of your mental health and emotional well-being following a cancer diagnosis.
- July 29, 2023: Updates from the 17th International Congress on MDS: Promising Treatment Advances @12 pm ET
Speaker: Moshe Mittelman MD; Professor of Medicine and Hematology, Tel Aviv Sourasky Medical Center
In this webinar, Dr. Moshe Mittelman will provide an overview of the most promising research presented at the 2023 17th International Congress on Myelodysplastic Syndromes impacting MDS diagnosis, prognosis, and management. After the presentation, there will be a Q & A session for participants.
- August 19, 2023: CHIP and CCUS, Precursors to MDS @12 pm ET
Speaker: Zhuoer Xie, MD, MS; Moffitt Cancer Center, Tampa, Florida
There have been marked developments in the understanding of clonal hematopoiesis based on findings of somatic mutations in genes known to be associated with MDS. This has led to newer terms to describe precursor states to MDS, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). This webinar will provide an overview of these conditions which may allow earlier diagnosis, modify surveillance for MDS, and guide additional therapies.
Learn from experts about treatment therapies and strategies for Patients & Caregiver LIVING with MDS.
Thank you to Bristol-Myers Squibb, Gilead, and Taiho for supporting these important events.